Obstetric complications associated with the lupus anticoagulant.
We identified eight patients with the lupus anticoagulant (an autoantibody acquired by some patients with systemic lupus erythematosus), by observation of an increased activated partial thromboplastin time and abnormal results on a tissue thromboplastin-inhibition test. The patients had experienced a total of 30 spontaneous abortions and fetal deaths in 31 previous pregnancies (96.8 per cent). During their next pregnancy, the patients were treated with 40 to 50 mg of prednisone per day and 81 mg of aspirin per day. The therapy shortened their activated partial thromboplastin times, produced normal values for tissue thromboplastin inhibition, and reduced the rate of pregnancy loss to 37.5 per cent. However, preeclampsia developed in the five patients who gave birth to live infants, and fetal growth retardation occurred in three cases. The corticosteroid and low-dose aspirin regimen appears to improve perinatal outcome in cases in which the mother has the lupus anticoagulant, but such practices as careful fetal surveillance and preterm delivery when appropriate are also important to successful obstetric management of such cases.
D000022:Abortion, Spontaneous / Q000209:etiology; D001241:Aspirin / Q000627:therapeutic use; D001779:Blood Coagulation Factors / Q000032:analysis / Q000037:antagonists & inhibitors*; D001780:Blood Coagulation Tests; D005260:Female; D005313:Fetal Death / Q000209:etiology; D005317:Fetal Growth Retardation / Q000209:etiology; D006801:Humans; D016682:Lupus Coagulation Inhibitor; D010314:Partial Thromboplastin Time; D011241:Prednisone / Q000627:therapeutic use; D011247:Pregnancy; D011248:Pregnancy Complications / Q000097:blood / Q000188:drug therapy / Q000209:etiology*
D001779:Blood Coagulation Factors; D016682:Lupus Coagulation Inhibitor; D001241:Aspirin; D011241:Prednisone